Mechanisms of disease: angiogenesis and the management of breast cancer (Q36922920)

17 August 2017

1 reference

title

Mechanisms of disease: angiogenesis and the management of breast cancer (English)

1 reference

17 August 2017

1 reference

1 reference

3

Alan Ashworth

1 reference

17 August 2017

2

Mitch Dowsett

1 reference

17 August 2017

1

Susana Banerjee

1 reference

17 August 2017

Lesley-Ann Martin

4

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Nature Clinical Practice Oncology

17 August 2017

published in

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

536-550

1 reference

Hypoxia reduces hormone responsiveness of human breast cancer cells

17 August 2017

cites work

1 reference

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

21 January 2018

1 reference

Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA

21 January 2018

1 reference

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

21 January 2018

1 reference

Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models

21 January 2018

1 reference

7 January 2021

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

7 January 2021

Pericytes and vascular stability

1 reference

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

7 January 2021

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

1 reference

7 January 2021

Tumorigenesis and the angiogenic switch

1 reference

7 January 2021

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

7 January 2021

The biology of VEGF and its receptors

1 reference

7 January 2021

Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells

1 reference

7 January 2021

Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells

1 reference

7 January 2021

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

1 reference

7 January 2021

Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy

1 reference

7 January 2021

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

1 reference

7 January 2021

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

1 reference

7 January 2021

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

1 reference

7 January 2021

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

1 reference

7 January 2021

Targeting lymphangiogenesis to prevent tumour metastasis

1 reference

7 January 2021

Hypoxia-inducible factor-1 in human breast and prostate cancer

1 reference

7 January 2021

Hypoxia--a key regulatory factor in tumour growth

1 reference

7 January 2021

Hypoxia signalling in cancer and approaches to enforce tumour regression

1 reference

7 January 2021

Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells

1 reference

7 January 2021

Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors

1 reference

7 January 2021

Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta

1 reference

7 January 2021

Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins

1 reference

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

7 January 2021

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

1 reference

7 January 2021

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

1 reference

7 January 2021

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

1 reference

7 January 2021

Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription

1 reference

7 January 2021

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

1 reference

7 January 2021

Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability.

1 reference

7 January 2021

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

1 reference

7 January 2021

Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia

1 reference

7 January 2021

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

1 reference

7 January 2021

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

7 January 2021

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

1 reference

7 January 2021

Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer

1 reference

7 January 2021

Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer

1 reference

7 January 2021

HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors

1 reference

7 January 2021

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

7 January 2021

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients

1 reference

7 January 2021

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma

1 reference

7 January 2021

Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?

1 reference

7 January 2021

Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

1 reference

7 January 2021

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast canc

1 reference

7 January 2021

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response

1 reference

7 January 2021

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

7 January 2021

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

1 reference

7 January 2021

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer

1 reference

7 January 2021

Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients

1 reference

7 January 2021

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma

1 reference

7 January 2021

Hypoxia-Inducible Factor-1 Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

1 reference

7 January 2021

Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

1 reference

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

7 January 2021

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

1 reference

7 January 2021

Association of genetic polymorphisms in the VEGF gene with breast cancer survival

1 reference

7 January 2021

Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis

1 reference

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

7 January 2021

Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression

1 reference

7 January 2021

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

7 January 2021

Disrupting tumour blood vessels

1 reference

7 January 2021

Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

1 reference

7 January 2021

Angiogenic inhibitors: a new therapeutic strategy in oncology

1 reference

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

7 January 2021

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

1 reference

7 January 2021

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

7 January 2021

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

7 January 2021

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

7 January 2021

From angiogenesis to neuropathology

1 reference

7 January 2021

Maximizing the potential of bevacizumab in cancer treatment

1 reference

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

7 January 2021

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

7 January 2021

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

7 January 2021

Identifiers

DOI

10.1038/NCPONC0905

1 reference

17 August 2017

1 reference